Sarepta Therapeutics (SRPT) – Hot Corp. News
-
Sarepta Therapeutics' (SRPT) EMBARK Study Did Not Meet Primary Endpoint but Data Shows Robust, Statistically Significant Results
-
Sarepta Therapeutics (SRPT) Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SRPT Stock Lookup